ASCO presentation: Phase II studies of PX-866 in solid tumors.What we know already: Phase I trials showed PX-866 to be well tolerated with some evidence of anti-cancer activity. Oncothyreon is conducting phase II studies of PX-866 in combination with other drugs in non-small cell lung cancer, glioblastoma, prostate cancer, colon cancer and head-and-neck cancer. Key questions: These studies are expected to complete patient enrollment by the end of the year. Oncothyreon is expected to present interim results from one or more of these trials at ASCO. >>To see these stocks in action, visit the 7 Cancer Drug Stocks to Know Right Now portfolio on Stockpickr. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.